DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Oncology Homepage

Robotic-assisted transhiatal esophagectomy is safe and effective for certain patients But it's a complex procedure to perform

Margarita Valdez American Society for Radiation oncology hires new assistant director of congressional relations

J. Michael Bruff Varian announces new VP of Investor Relations

Louisiana hospitals deploy Synaptive's BrightMatter technology Builds on earlier investments in neuroscience

Varian to market Bionix brachytherapy applicators in North America Two tools for treating upper GI and anal/rectal cancers

Accuray’s TomoTherapy more effective than Varian’s RapidArc, non-randomized study finds French study examined outcomes for 166 patients

Cancer patient in Italy first to undergo Varian HyperArc radiotherapy Delivers compact radiation doses to tumors with improved targeting

New PET tracer for prostate cancer shows benefits over current standard: study 11C-sarcosine could also be used for other cancers

Praveen Dalmia Karmanos Cancer Institute appoints new corporate director of Oncology Technology & Innovation

Accuray's iDMS cleared by FDA for use with TomoTherapy Centralized Data Management System platform for workflow efficiency

Gap between insurance policy language
and final decisions

Study finds majority of insurance denials overturned in pediatric proton patients

by Lauren Dubinsky , Senior Reporter
New research from Penn Medicine revealed that even though one in 10 pediatric cancer patients are initially denied coverage for proton therapy, nearly all ultimately receive approval.

“Because of the different way it moves within the body, proton radiotherapy can often spare normal tissues better than photon radiotherapy,” Dr. Eric Ojerholm, co-author of the study and radiation oncology instructor at Penn, told HCB News. “Cured pediatric patients are likely to live for a long time and be at risk for late toxicities from radiation, and pediatric developing normal tissues are more sensitive to effects from radiation than are adult tissues.”

Story Continues Below Advertisement

qualiTEE - reliabiliTEE - repairabiliTEE - we guaranTEE

Bayer HealthCare Multi Vendor Service will repair your transducer with the same precision and care you provide to your patients. Now offering TotalREPAIR on 140 transducer models! Call us at 1-844-5100 or visit www.mvs.bayer.com to set up an order today.



For the study, Ojerholm and his team evaluated five years' worth of insurance coverage data at Penn’s Roberts Proton Therapy Center, from 2010 to 2015. Out of the 287 cases, 89 percent were approved outright and 11 percent were initially denied.

After appeals were made, 97 percent of the denied cases were overturned and approved. However, a great deal of time and resources were wasted in that process.

The team uncovered that most of the denials were due to the age of the patient and the type of tumor they had. Some patients over age 18 develop a type of cancer that physicians deem pediatric because of how the tumor behaves.

Those cancers include neuroblastoma, rhabdomyosarcoma, germinoma and Ewing sarcoma. Physicians usually treat the cancer the same way they would treat a pediatric patient, but this patient population was initially denied four times as often as those 18 or younger.

In addition, cancers located outside the brain or spine were 4.5 times more likely to be denied. That may be due to the fact that the strongest evidence for pediatric proton therapy involves brain and spine tumors.

The appeal process took about a week on average and involved letters, peer-to-peer phone calls, or both in some cases. In 28 percent of the cases, multiple rounds of appeal were required before coverage was finally approved.

The team cautions that the study had limitations and that research will have to be conducted in other regions of the U.S. to confirm these results. A center in another part of the country would have its own mix of insurance carriers and plans, which could lead to different findings.

Penn also has an advisory board that assesses patients for proton therapy and only recommends those most likely to benefit from treatment. If another center skips that step, they may have more denials or fewer appeal reversals.

Ojerholm believes that there should be a way to streamline the approval process. He suggests changing the language of insurance policies to recognize the distinction of pediatric tumors, and classifying patients between ages 19 and 30 with pediatric cancers as pediatric cases.

“If the results are confirmed [in another study], then as a second step we could alert insurance companies to these data,” he said. “Ideally, this would prompt a discussion about ways to streamline the approval process for pediatric patients.”

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED